Leaflet ILARIS 150mg powder for injection

Indicated for: autoimmune inflammatory diseases

Substance: canakinumab (monoclonal antibody)

ATC: L04AC08 (Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors)

Canakinumab is a monoclonal antibody used for the treatment of rare inflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) and systemic juvenile idiopathic arthritis (sJIA). It works by inhibiting interleukin-1 beta (IL-1β), a protein involved in inflammation.

The medication helps reduce inflammation, fever, and other symptoms associated with these conditions. It is administered as a subcutaneous injection, usually once every few weeks, as directed by a doctor.

Canakinumab is used under strict medical supervision, and patients should be monitored for signs of infections or other adverse reactions. It is important to inform the doctor about any other medications being taken or pre-existing conditions.

Side effects may include injection site reactions, respiratory infections, headaches, or, in rare cases, severe allergic reactions. Patients should report any unusual symptoms to their doctor.